Peptide Atlas · Peptide

Cagrilintide

Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone that induces satiety; in a 26-week phase 2 trial in 706 adults with overweight or obesity, once-weekly doses reduced body weight by 6.0% to 10.8% against 3.0% on placebo, with more nausea.

established

provisional
PubChem 171397054
2 citations
0 discussions
0 followers
AM833
NN0174-0833
NN9838
long-acting amylin analog

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Cagrilintide. Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Once-weekly cagrilintide reduced body weight dose-dependently in a phase 2 trial	emerging	pmid 34798060
Cagrilintide with semaglutide (CagriSema) reduced body weight by 20.4% at 68 weeks (phase 3a)	established	pmid 40544433

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.